No Data
Trending Stocks Today: NANO Nuclear Energy Inches up 8.83% Post-Market
Sector Update: Health Care Stocks Steady Premarket Friday
Ocugen's Receives Nod to Enrol in High Dose Study of Stargardt Disease Drug Candidate
Express News | Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in Gardian Study for Stargardt Disease
Ocugen Announces Data and Safety Monitoring Board Approves Enrollment in High Dose Cohort 3 in GARDian Study for Stargardt Disease
Express News | Ocugen Shares Are Trading Lower. The Company Announced That the First Patient Has Been Dosed in Its Phase 3 LiMeliGhT Clinical Trial for OCU400—a Modifier Gene Therapy Product Candidate Being Developed for Retinitis Pigmentosa
103045055 : why ? what did you see from this share ? just curious